Run-in periods in randomized trials: Implications for the application of results in clinical practice

JAMA

Volumn 279, Issue 3, 1998, Pages 222-225

  Pablos Méndez, Ariel ^a,b,c   Barr, R Graham ^a   Shea, Steven ^a,b  

^a Columbia University ^*  (United States)

^b School of Public Health ^*  (United States)

^c Division of General Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAFETY; SCREENING;

EID: 2642616191     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.3.222     Document Type: Article

References (37)

1. Pocock SJ. Statistical aspects of clinical trial design. Statistician. 1982;31:1-18.
2. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, part I. Br J Cancer. 1976;34:585-612.
3. From trial outcomes to clinical practice. Drug Ther Bull. 1996;34:38-40.
4. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation (CBER). Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products (Draft). Available at: http://www.fda.gov/CBER/cberftp.html. Accessed March 13, 1997.
5. Hennekens CH. Issues in the design and conduct of clinical trials. J Natl Cancer Inst. 1984;73:1473-1476.
6. Meinert CL, Tonascia S. Clinical Trials: Design, Conduct, and Analysis. New York, NY: Oxford University Press; 1986.
7. Haynes RB, Dantes R. Patient compliance and the conduct and interpretation of therapeutic trials. Control Clin Trials. 1987;8:12-19.
8. Schork MA, Remington RD. The determination of sample size in treatment-control comparisons for chronic disease studies in which drop-out or non-adherence is a problem. J Chronic Dis. 1967;20:233-239.
9. Peduzzi P, Detre K, Wittes J, Holford T. Intent-to-treat analysis and the problem of crossovers. J Thorac Cardiovasc Surg. 1991;101:481-487.
10. Newell DJ. Intention-to-treat analysis. Int J Epidemiol. 1992;21:837-841.
11. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in incidence of coronary heart disease. JAMA. 1984;251:351-364.
12. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
13. Lang JM. The use of a run-in to enhance compliance. Stat Med. 1990;9:87-95.
14. Perez V, Gilabert I, Faries D, Alvarez E, Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet. 1997;349:1594-1597.
15. The CAST (Cardiac Arrhythmia Suppression Trial) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321:406-412.
16. Davis KL, Thal LJ, Gamzu ER, et al, and the Tacrine Collaborative Study Group. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med. 1992;327:1253-1259.
17. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation. 1995;92:212-218.
18. Packer M, Bristow MR, Cohn JN, et al, for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
19. Lang JM, Buting JE, Rosner B, Cook N, Hennekens CH. Estimating the effect of the run-in on the power of the Physicians' Health Study. Stat Med. 1991;10:1585-1593.
20. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ. 1988;296:313-316.
21. Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. Is this patient taking the treatment as prescribed? JAMA. 1993;269:2779-2781.
22. Schechtman KB, Gordon ME. A comprehensive algorithm for determining whether a run-in strategy will be a cost-effective design modification in a randomized clinical trial. Stat Med. 1993;12:111-128.
23. Brittain E, Wittes J. The run-in period in clinical trials: the effect of misclassification on efficiency. Control Clin Trials. 1990;11:327-338.
24. Blackwelder WC, Hastings BK, Lee ML, Deloria MA. Value of a run-in period in a drug trial during pregnancy. Control Clin Trials. 1990;11:187-198.
25. Casella G, Berger RL. Statistical Inference. Pacific Grove, Calif: Wadsworth & Brooks/Cole Advanced Books & Software; 1990:section 7.4.2.
26. Sackner-Bernstein JD, Krum H, Goldsmith RL, et al. Should worsening heart failure early after initiation of beta-blocker therapy for chronic heart failure preclude long-term treatment? Circulation. 1995;92(suppl I):395. Abstract 1881.
27. Louis TA, Lavoru PW, Bailar JC, Polansky M. Crossover and self-controlled designs in clinical research. N Engl J Med. 1984;310:24-31.
28. Packer M, Gheorghiade M, Young JB, et al, for the RADIANCE Study. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. N Engl J Med. 1993;329:1-7.
29. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-533.
30. Senn SJ. Clinical trials and epidemiology. J Clin Epidemiol. 1990;43:628-632.
31. Sackett DL. The competing objectives of randomized trials. N Engl J Med. 1980;303:1059-1060.
32. Liberati A. The relationship between clinical trials and clinical practice: the risks of underestimating its complexity. Stat Med. 1994;13:1485-1491.
33. Guyatt GH, Sackett DL, Cook DJ, for the Evidence-Based Medicine WorkingGroup. Users' guides to the medical literature, II: how to use an article about a therapy or prevention, B: what were the results and will they help me in caring for my patients? JAMA 1994;271:59-63.
34. Stienen U. The once-daily dose regimen of carvedilol: a meta-analysis approach. J Cardiovasc Pharmacol. 1992;19(suppl 1):S128-S133.
35. Rutten-van Molken MP, van Doorslaer EK, van Vliet RC. Statistical analysis of cost outcomes in a randomized controlled clinical trial. Health Econ. 1994;3:333-345.
36. The Asilomar Working Group on Recommendations for Reporting of Clinical Trials in the Biomedical Literature. Checklist of information for inclusion in reports of clinical trials. Ann Intern Med. 1996;124:741-743.
37. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA. 1996;276:637-639.